Medical - Diagnostics & Research · NASDAQ
Current Price
$192.82
PE Ratio (TTM)
32.7x
Intrinsic Value
$200.45
+3.8% margin of safety
COMPETITIVE MOAT
↑Dominant Sequencing Technology
Illumina's proprietary sequencing-by-synthesis technology offers superior accuracy and throughput. This entrenched position creates high switching costs for customers invested in their ecosystem.
↑Extensive Installed Base
A vast installed base of NovaSeq instruments creates a recurring revenue stream from consumables. This scale advantage makes it difficult for competitors to displace Illumina's market share.
↑Expanding Multiomics and AI Integration
Illumina's strategic expansion into multiomics and AI-driven solutions enhances its platform's value. This integration deepens customer reliance and creates a data-driven ecosystem advantage.
INVESTMENT RISKS
↓Regulatory Scrutiny and Antitrust Concerns
Illumina has faced significant regulatory scrutiny, particularly regarding its past acquisitions. Future regulatory challenges could impact its strategic flexibility and growth opportunities.
↓Dependence on Key Instrument Sales
While consumables provide recurring revenue, a significant portion of Illumina's revenue is tied to instrument sales. A slowdown in capital expenditure by customers could impact overall financial performance.
↓Execution Risk in New Market Ventures
Expanding into multiomics and AI requires successful execution and integration of new technologies and business models. Failure to effectively capitalize on these opportunities could hinder future growth.
Base case
A base case PE valuation for ILMN estimates a fair value of about $200.45 per share, against a current price of $192.82. The model assumes 7.6% annual earnings growth, a 32.52x target PE multiple, and a 10% discount rate.
Intrinsic Value
$200.45
Margin of safety
+3.8%
Expected annual return
+0.8%
Base case assumptions: 7.6% annual earnings growth, 32.52x target PE, 10% discount rate, 5 year projection. Data as of 2026-11-20.
This base case uses default assumptions and is not financial advice. The fair value changes significantly when the target PE or earnings growth rate changes. Open the calculator to set your own assumptions and see the full sensitivity range.
Adjust the target PE, earnings growth, and discount rate to see how the fair value and margin of safety for Illumina, Inc. respond.
Open PE Calculator for ILMNIllumina, Inc. specializes in delivering advanced genetic and genomic analysis tools, primarily through sequencing and array technologies. The company's offerings empower clients across various sectors to integrate genomic insights into both research and clinical environments, with applications spanning critical fields like life sciences, cancer diagnostics, reproductive health, agriculture, and innovative new domains. Illumina's portfolio encompasses specialized instrumentation and necessary consumables for genetic analysis, alongside comprehensive genotyping and sequencing services. They also offer instrument maintenance agreements, collaborate through development and licensing deals, and perform cancer detection tests. Its diverse clientele comprises leading genomic research facilities, universities, state-funded laboratories, medical centers, pharmaceutical and biotechnology firms, commercial molecular diagnostic providers, and businesses focused on consumer genomics. Illumina employs a two-pronged distribution strategy, selling directly to clients across North America, Europe, Latin America, and the Asia-Pacific. Additionally, it partners with life-science distributors to reach markets in Europe, the Asia-Pacific, Latin America, the Middle East, and Africa. Established in 1998, the company maintains its corporate headquarters in San Diego, California.
PE Ratio (TTM)
32.7x
PEG Ratio
1.04
Earnings Yield
3.07%
ROE (TTM)
31.5%
Revenue/Share (TTM)
$30.05
Debt/Equity
0.74x
The trailing twelve-month PE ratio of ILMN reflects how much investors pay per dollar of Illumina, Inc.'s earnings. This metric is most useful when compared to Medical - Diagnostics & Research peers and the company's own historical range.
ILMN's PE of 32.7x combined with a PEG ratio of 1.04 provides a growth-adjusted perspective. A PEG near 1.0 means the P/E is roughly in line with the earnings growth rate. Keep in mind that PE-based valuation works best for profitable, mature companies — for high-growth or cyclical Medical - Diagnostics & Research, a DCF analysis may be more appropriate.
To value Illumina, Inc. using PE: (1) Compare the current PE (32.7x) against the Medical - Diagnostics & Research median to assess relative pricing, (2) check the PEG ratio (1.04) to adjust for growth expectations, (3) review the 5-year PE range to identify where the stock sits historically, and (4) estimate fair value by multiplying a target PE by forward EPS estimates. This relative approach complements DCF's absolute valuation.
ILMN's PEG ratio is 1.04, calculated by dividing the PE ratio (32.7x) by the expected earnings growth rate. A PEG near 1.0 means the P/E is roughly in line with the expected earnings growth rate. Note that PEG accuracy depends on the reliability of growth estimates.
PE ratio gives a quick relative read — how ILMN is priced versus Medical - Diagnostics & Research peers. DCF provides an absolute value based on projected free cash flows. For ILMN, with a strong ROE of 31.5%, both methods are worth using — PE for a market-relative check, DCF to stress-test whether fundamentals justify the price. Each method has blind spots: PE ignores capital structure and cash flow quality, while DCF is sensitive to growth and discount rate assumptions.
P/E and DCF value ILMN with different methods and assumptions, so the two conclusions can differ. Compare the DCF intrinsic value.
Price as of 2026-11-20. Financial data from Financial Modeling Prep (trailing twelve months) · Valuation methodology by Charlie Wang.
This is an estimate, not investment advice.